Differences in the Quality of Information on the Internet about Lung Cancer between the United States and Japan Yasushi Goto, MD, Ikuo Sekine, MD, PhD,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis Erik.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Katsuyuki Kiura,

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis Erik.

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study Kaoru Kubota, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Frank Detterbeck, MD Journal of Thoracic Oncology

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third- Line Chemotherapy for Small Cell Lung Cancer Satoshi Igawa, MD, PhD,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer Gyo Asai, MD, PhD, Nobuyuki.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Ayman O. Soubani, MD, John C. Ruckdeschel, MD

A Primer on Health Economic Evaluations in Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

The Number of Pulmonary Metastases: Influence on Practice and Outcome

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Pulmonary Metastasectomy in Breast Cancer

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

The Port Site Recurrence after a Thoracoscopic and Video-Assisted Esophagectomy for Advanced Esophageal Cancer Satoshi Yamamoto, PhD, Katsunobu Kawahara,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Table of Contents Journal of Thoracic Oncology

Genetic Changes in Squamous Cell Lung Cancer: A Review

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Yasunori Sato,

David Garfield, MD Journal of Thoracic Oncology

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Epidemiology of Thymoma and Associated Malignancies

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer:

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Differences in the Quality of Information on the Internet about Lung Cancer between the United States and Japan Yasushi Goto, MD, Ikuo Sekine, MD, PhD, Hiroshi Sekiguchi, MD, Kazuhiko Yamada, MD, Hiroshi Nokihara, MD, Noboru Yamamoto, MD, Hideo Kunitoh, MD, Yuichiro Ohe, MD, Tomohide Tamura, MD Journal of Thoracic Oncology Volume 4, Issue 7, Pages 829-833 (July 2009) DOI: 10.1097/JTO.0b013e3181a76fe1 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 JAMA benchmark: Description of the JAMA benchmark16 is listed by the search engines; display of authorship (authors and contributors, their affiliations, and relevant credentials); attribution (references and sources for all content, and all relevant copyright information); disclosure (Web site ownership, sponsorship, advertising, commercial funding arrangements or support, or potential conflicts of interest); and currency (dates on which the contents were posted and updated). Journal of Thoracic Oncology 2009 4, 829-833DOI: (10.1097/JTO.0b013e3181a76fe1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Evaluations of the treatment description in the Web sites: The treatment description is classified into three categories: acceptable (description of the systematic review such as guidelines from authorized facilities17–20; links to systematic reviews; abstracts of systematic reviews), unacceptable (recommendation of alternative medicine or a generally unapproved treatment), and invaluable (lack of description). Journal of Thoracic Oncology 2009 4, 829-833DOI: (10.1097/JTO.0b013e3181a76fe1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Administrators of the Web sites: Administrators were classified into five categories: NPO (nonprofit organization) or public institution, medical institution, commercial (for the specific treatments), personal (pages made by patients or their families), and others. Journal of Thoracic Oncology 2009 4, 829-833DOI: (10.1097/JTO.0b013e3181a76fe1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions